B E Elewski
Elewski B, Rich P, Pollak R, Pariser D, Watanabe S, Senda H, et al
. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600-8 pubmed publisher
..A period of 52 weeks may be too brief to evaluate a clinical cure in onychomycosis. Once daily topical efinaconazole appears to be a viable alternative to oral treatment options for onychomycosis. ..
Elewski B, Aly R, Baldwin S, González Soto R, Rich P, Weisfeld M, et al
. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62-9 pubmed publisher
..7%), erythema (1.6%), and dermatitis (1.3%). Duration of follow-up is a limitation. Tavaborole demonstrates a favorable benefit-risk profile in treatment of toenail onychomycosis. ..
Elewski B. Tinea capitis: a current perspective. J Am Acad Dermatol. 2000;42:1-20; quiz 21-4 pubmed
..With these changes, prospects for newer therapies with the novel antimycotic agents itraconazole, fluconazole, and terbinafine are reviewed. (J Am Acad Dermatol 2000;42:1-20.)..
Elewski B, Cáceres H, DeLeon L, El Shimy S, Hunter J, Korotkiy N, et al
. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol. 2008;59:41-54 pubmed publisher
..Alternative antifungal therapies with shorter/simpler treatment regimens may be important to develop for this indication...